Project Grant R01CA310898
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $639K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Portland, OR 97239, USA
Similar Awards
- The National Cancer Institute, part of the Department of Health and Human Services, awarded Oregon Health & Science University $657,007 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop a multiscale approach to controlling cellular interactions in premalignant tissues. The project aims to use physical science methods to manipulate interactions between multiple cell types in precancerous tissues to restore normal tissue function. The recipient will...
- This $683,472 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the University of Cincinnati to develop a novel targeted therapy for acute myeloid leukemia (AML). The key objectives are to therapeutically target the DHODH enzyme to induce AML cell differentiation, activate the immune system, and induce ferroptosis-mediated cell death. This approach aims to better differentiate AML cells from normal hematopoietic stem cells and enhance...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded Albert Einstein College of Medicine $431,970 under the Cancer Treatment Research program (CFDA 93.395) on April 1, 2026, to investigate combination approaches to acute myeloid leukemia targeting both CD123-directed NK cell engagers and BCL-2 inhibition through venetoclax. The research will employ dynamic BH3 profiling to probe mitochondrial priming mechanisms and test whether...
- The National Cancer Institute awarded Oregon Health & Science University $625,179 on March 26, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and validate direct and indirect MCL1 inhibitor therapies for lung metastasis in osteosarcoma. The research deploys a bioengineered bone and lung model with real-time cell tracking to establish MCL1's role in osteosarcoma lung metastasis and identify the most effective MCL1 inhibitors for eliminating metastases in engineered...
- The National Cancer Institute awarded Cincinnati Children's Hospital Medical Center $522,196 on July 20, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate non-canonical BRAF mutations in acute myeloid leukemia development and therapeutic response. The recipient will conduct research to delineate how BRAF mutations contribute to leukemogenesis, disease phenotype, and therapeutic resistance in AML patients who exhibit dismal survival outcomes regardless of treatment...
- The National Cancer Institute, a division of the Department of Health and Human Services, awarded the University of Illinois $422,649 as a Project Grant (R21CA303745) on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396). The award funds research into racial disparities in acute myeloid leukemia (AML) treatment outcomes. The study examines whether NPM1 mutant status determines FOXM1 cytoplasmic localization and inactivation in primary bone marrow samples from Black AML...
- The National Cancer Institute awarded Northwestern University $593,307 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate molecular mechanisms underlying nucleophosmin 1 (NPM1)-driven acute myeloid leukemia leukemogenesis. The funded research examines how NPM1 cytoplasmic mutations (NPM1c), which occur in approximately 30 percent of adult de novo AML cases, cooperate with clonal hematopoiesis mutations in DNMT3A, TET2, or IDH1/2 to promote leukemic...
- The National Cancer Institute awarded Oregon Health & Science University $1.312 million on July 10, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop a patient-derived intestinal organoid system modeling gastrointestinal toxicity associated with immune checkpoint inhibitors used in cancer treatment. The funded work will develop air-liquid interface organoid cultures preserving epithelial and immune components from human colon mucosa to model immune-related adverse...
- The National Cancer Institute awarded The Johns Hopkins University $155,479 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and validate an antibody-drug conjugate targeting CCRL2 for treatment of high-risk myelodysplastic syndrome and myelodysplastic syndrome-related acute myeloid leukemia, particularly in patients with TP53 mutations. The funded work includes patient-derived xenograft studies and assessment of the anti-CCRL2 ADC efficacy and safety in an...
- The National Cancer Institute awarded Oregon Health & Science University $1,042,004 on March 26, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop a microphysiological bone metastasis-on-a-chip platform that models prostate cancer metastasis into vascularized and innervated bone tissue. The research platform incorporates a mineralized, osteocyte-embedded bone matrix supporting active osteoclast and osteoblast remodeling, perfusable pericyte-supported vasculature to...